𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Functional interactions between interleukin-4, interleukin-2, and tumor necrosis factor-al for lymphokine-activated killer cell generation

✍ Scribed by Jean Yves Blay; Didier Branellec; Eric Robinet; Francoise Gay; Salem Chouaib


Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
450 KB
Volume
4
Category
Article
ISSN
0887-8013

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The purpose of the present study was to explore the interaction between interleukin‐2 (IL‐2), interleukin‐4 (IL‐4), and tumor necrosis factor‐a (TNF) on the differentiation of human large granular lymphocytes (LGL) into lymphokine‐activated killer cells (LAK). The data show that recombinant human IL‐4 (100‐1,000 U/ml) was able to induce the differentiation of human LGL into LAK effectors. The levels of the IL‐4‐induced cytotoxicity are significantly lower than those observed after stimulation of LGL by optimal doses of IL‐2. This LAK activity generation by IL‐4 was not associated with LGL proliferation. When TNF was added in LGL culture in the presence of sub‐optimal concentrations of IL‐4, the lytic capacity of the activated killer cells was significantly enhanced, suggesting an apparent synergy between these two factors. Most interestingly, our data indicate that exogenous TNF can partially overcome the known inhibitory effect of IL‐4 on IL‐Pinduced LGL differentiation into LAK effectors. These findings suggest a role for TNF in the process of LAK induction.


📜 SIMILAR VOLUMES


Tumor-derived transforming growth factor
✍ Nadia Delens; Els Torreele; Huub Savelkool; Patrick de Baetselier; Luc Bouwens 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 599 KB

Adherent lymphokine-activated killer (A-LAK) cells are purified IL-2 activated natural killer (NK) cells with potent antitumor cytotoxic activity. They have been used in the adoptive immunotherapy of metastatic cancers. However, it has been shown that intravenously transferred IAK cells have a poor

Lack of correlation between peripheral b
✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t